Lung cancer targeted therapy: which test results change treatment?
Targeted therapy becomes relevant when a test identifies a cancer alteration that matches a treatment in the right clinical setting. The gene name is only part of the answer. A mutation, fusion, amplification and protein-expression result can lead to different options, even when they involve the same gene. Ask the oncologist which finding is actionable now, which may become relevant later and which has no established treatment role.
On this page
Find the result that actually changes the plan
A molecular report may list many findings, but only some support a treatment decision. An actionable alteration has evidence linking it to a treatment in a defined cancer setting. Other findings may be biologically interesting or suitable for research without directing routine care.
Ask the clinician to point to the exact alteration used to choose your medicine. Keep the laboratory wording, including exon number or fusion partner when reported. This discussion is about what the result means for treatment; assembling and transferring the report is a separate practical task.
Sources and references: [1]
The type of alteration matters as much as the gene
EGFR exon 19 deletions and many EGFR exon 20 insertions respond to different treatment approaches. MET exon 14 skipping and MET amplification describe different biological events. HER2 mutation and HER2 protein overexpression also require different interpretations.
A report headed positive can therefore be too vague for a treatment decision. Ask whether the result comes from sequencing, a protein stain or another test, and which type of alteration it demonstrates. This prevents a drug mentioned for one biomarker category being chosen on the basis of another.
Common groups of targets in NSCLC
In advanced NSCLC, clinically relevant targets include selected changes involving EGFR, ALK, ROS1, BRAF, RET, MET, NTRK, KRAS and HER2. The treatment may be a tablet, an antibody or a combination. Some medicines are used first; others require prior systemic treatment.
Rather than memorizing drug names, ask for a short explanation of the match: this alteration, in this cancer, at this stage of treatment. The answer should also identify the approved local use or research setting, since a treatment pathway described in another country may differ.
Sources and references: [2]
Why tissue and blood testing may complement each other
Tissue establishes the cancer's histology and can provide material for molecular and protein tests. A liquid biopsy examines tumor-related material in blood and can be useful when tissue is difficult to obtain or when cancer has changed after treatment.
A negative blood result may occur because too little tumor DNA is present. If finding a target would change therapy, discuss tissue testing or another sampling approach. Conversely, repeating an invasive biopsy solely to reproduce an already clear result may not be necessary. Ask what additional information the procedure is meant to provide.
Handle uncertain and inherited findings separately
A variant of uncertain significance has an unclear effect and usually should not be used to select treatment. A long report can contain several such findings without changing the recommended drug. Ask which entries are being set aside and why.
Tumor testing can occasionally suggest an inherited alteration. Confirming that possibility may require a separate germline test and genetic counseling. A change found in a cancer cell is not automatically a result that children or siblings share.
Sources and references: [1]
Treatment history changes the interpretation
An alteration found at diagnosis can guide the first therapy. A new alteration after progression may help explain resistance and suggest a subsequent option. The same result can therefore have a different practical meaning depending on what the cancer has already been exposed to.
Keep a dated treatment list alongside the laboratory report. If a targeted medicine is being proposed again, ask whether it addresses a newly identified resistance mechanism, reuses a previously effective approach or forms part of a trial. The reason matters more than the label targeted.
Compare benefits with the monitoring burden
Targeted drugs can cause rash, diarrhea, swelling, liver abnormalities or other treatment-specific problems. Some require heart or lung monitoring. A matched target makes a medicine relevant; the remaining decision still considers health conditions, interactions and the ability to attend follow-up.
Ask how response will be assessed, what side effects should prompt contact and what the alternative is if the medicine is poorly tolerated. Do not change the dose or combine targeted drugs based on a molecular report without the prescribing team's direction.
Sources and references: [4]
Turn the result into a focused Shanghai inquiry
A Shanghai review is most useful when it addresses a specific question: a rare alteration, conflicting test results, resistance after treatment or the local availability of a matched approach. EastMedGo can help prepare an inquiry using the pathology and molecular-review service information.
Share the full report, pathology and treatment timeline, then identify the decision you need answered. We can help clarify appointment requirements and coordination arrangements. This keeps the consultation centered on a treatment choice rather than ordering another broad panel without a clear purpose.
Common questions
Does every mutation have a targeted drug?
No. Some alterations have established matched treatments, some are being studied and others do not guide therapy. A variant of uncertain significance generally should not be used as the reason to prescribe a targeted medicine.
Sources and references: [1]
Does a negative blood test rule out a target?
No. A blood sample may contain too little tumor DNA to detect a relevant alteration. The team may recommend tissue testing if the result would change treatment and an appropriate sample can be obtained.
Will the targeted medicine replace every other treatment?
Not necessarily. It may be used alone, in a defined combination or at a particular point before or after other treatment. Brain metastases, a painful lesion or local progression may still need separate assessment.
Sources and references: [2]
Sources and references
- Biomarker Testing for Cancer Treatment
- Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
- Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care
- Targeted Therapy to Treat Cancer
Prepared with AI assistance by EastMedGo for patients comparing treatment and care options.